Transparency Market Research’s report, titled “H1N1 Vaccination Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” highlights the leading factors driving the global H1N1 vaccination market and sheds light on the various challenges that it faces during the forecast period of 2015 to 2023.
The term H1N1 influenza or ‘swine flu’ refers to a kind of influenza observed in pigs and occasionally transmitted to human beings, mostly through veterinarians and hog farmers. The prevalence of swine flu has been on the rise around the world since the spring of 2009. This is why this infection was declared as a global pandemic by the World Health Organization (WHO). This influenza virus tends to infect the lining of the cells in the human nose, lungs, and throat. The virus enters the human body by inhalation of contaminated droplets or with the transfer of live viruses via a contaminated surface to the nose, mouth, or eyes. The H1N1 vaccine is formulated to protect against this influenza virus. This vaccine works by stimulation of the immune system of the body by making it produce antibodies against the flu virus, thus helping the human body to fight the infection.
Read Full Report: http://www.transparencymarketresearch.com/h1n1-vaccination-market.html
Increase in Immune Deficiency Diseases owing to Growing Aging Population to Propel H1N1 Vaccination Market
The market has been stimulated by the introduction of brands such as Fiuarix (GSK Pharmaceuticals Ltd), Agripal (Panacea Biotec Ltd), Influgen (Lupin Laboratories Ltd.), Nasovac (Serum Institute of India Ltd.), Influvac (Solvay Pharma India Pvt Ltd), and Vaxigrip (Sanofi Pasteur), among others.
The global market for H1N1 vaccination is predicted to be fuelled in the coming years by the rise in swine flu cases. The growth of the aging demographic further increases the risk of contracting diseases such as immune deficiency diseases and respiratory tract infections and thereby increases the risk factor of getting H1N1 influenza. Some other factors such as the increasing government support and the rise in the activities of research within the field of vaccine technologies are also boosting the growth prospects of the H1N1 vaccination market. On the other hand, factors such as the absence of awareness and lack of experienced medical professionals may impede the growth of the market in the coming years. In addition, strict regulations and high capital needs have also hindered the development of the global market for H1N1 vaccination.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6913
Europe and North America Constitute the Biggest Share in the Market
In terms of regional segmentation, the market is segmented into Asia , North America, the Middle East and Africa, Latin America, and Europe. Amongst these, on the basis of revenue, Europe and North America constitute the biggest share in the market owing to the established research infrastructure in these regions. Within North America, the U.S. constitutes the biggest share in the market and is trailed by Canada. On the other hand, France and Germany led the H1N1 vaccination market in the European region. The H1N1 vaccination market in Asia is predicted to exhibit a huge growth rate in the forthcoming years owing to the rising awareness amongst people on the disease, along with the increasing number of programs and initiatives taken by governments for increasing awareness amongst the masses on the H1N1 influenza virus and other similar diseases.
The prominent players operating in the market include Medimmune, AstraZeneca plc., GlaxoSmithKline, Novartis, Sanofi Pasteur, Sinovac, Baxter, Zydus Cadila, and Commonwealth Serum Laboratories, among others.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453